• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

AbbVie

10 leading pharma executives you need to know

April 25, 2022 By Brian Buntz

Given the complexity of the pharmaceutical business, it can be challenging to gauge the performance of any chief executive in the space. That said, CEOs’ annualized return over tenure as CEO over their term can hint at performance. In addition, rating sites like Glassdoor also indicate CEOs’ popularity. Here, we parsed a range of metrics, […]

Filed Under: Blog, Business/Financial News, Featured, News Well, Pharmaceutical Tagged With: AbbVie, Argenx, Eli Lilly, Evotec, Genmab, leadership, Novo Nordisk, Pfizer, Pharma 50, pharma execs, Sartorius Stedim Biotech, Thermo Fisher Scientific, West Pharmaceutical Services

AbbVie receives positive opinion from CHMP for injection that treats psoriatic arthritis

October 15, 2021 By Sean Whooley

AbbVie (NYSE:ABBV) announced today that a European governing body recommended approval for its psoriatic arthritis treatment injection. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of risankizumab (SKYRIZI, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate […]

Filed Under: Drug-Device Combinations, Pharmaceutical, Regulatory/Compliance Tagged With: AbbVie, European Commission

50 of 2020’s best-selling pharmaceuticals

May 17, 2021 By Brian Buntz

Drug sales in 2020 proved more resilient than many experts anticipated in the early days of the pandemic. Still, the impact on many injectable drugs was tangible in the first half of the year as hospitals initially dissuaded patients from seeking in-person treatment. But sales were generally strong for the full year. AbbVie’s injectable biologic […]

Filed Under: Featured, Pharmaceutical Tagged With: AbbVie, adalimumab, aflibercept, apixaban, Bayer, Biktarvy, Bristol-Myers Squibb, dupilumab, Dupixent, Eliquis, Eylea, Humira, ibrutinib, Imbruvica, Keytruda, lenalidomide, Merck, pembrolizumab, Pfizer, Regeneron Pharmaceuticals, Revlimid, rivaroxaban, Stelara, ustekinumab, Xarelto

NIH launches drug trial for deadly cytokine storm

October 16, 2020 By Sean Whooley

The National Institutes of Health today launched a Phase 3 clinical trial to evaluate three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes proteins that trigger inflammation, otherwise known as a cytokine storm, which can lead to acute respiratory distress syndrome, multiple […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Pharmaceutical Tagged With: AbbVie, Bristol-Myers Squibb Co., coronavirus, COVID-19, Janssen Pharmaceuticals, Johnson & Johnson, National Institutes of Health (NIH)

FDA: Thousands of new breast-implant-related illnesses reported

August 20, 2020 By Nancy Crotti

The FDA today reported that it has received nearly 2,500 new reports globally of “breast implant illness” or BII. Reports of new breast implant-related cancer were also up. BII is not cancer, nor is it a term often found in medical literature, the agency said. But it is frequently used by patients and healthcare providers […]

Filed Under: Featured, Oncology, Women's Health Tagged With: AbbVie, Allergan, BIA-ALCL, FDA

The most innovative pharmaceutical agents of 2020

August 3, 2020 By Danielle Kirsh

The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, […]

Filed Under: Cardiovascular, Featured, Neurological, Oncology, Pharmaceutical Tagged With: AbbVie, Adlon Therapeutics, Advanced Accelerator Applications, Astellas Pharma, Bayer, Eli Lilly & Co., Galien Foundation, Genentech, Greenwich Biosciences, GW Pharmaceuticals, Janssen Biotech, Johnson & Johnson, Karyopharm Therapeutics, Medicines Development for Global Health, Merck, Novartis, Pfizer, Population Council, Purdue Pharma, Roche Group, Servier Pharmaceuticals, SIGA Technologies, Sobi, TB Alliance, Theravance Biopharma

Allergan, Ideal Implant targets of FDA warning letters

May 14, 2020 By Nancy Crotti

The FDA issued warning letters today to two breast implant manufacturers for failure to comply with regulatory requirements. One letter went to Allergan (now part of AbbVie) for failing to comply with requirements — under two separate premarket approval orders — to conduct post-approval studies to assess the long-term safety and risks of two models of […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Implants, Regulatory/Compliance, Women's Health Tagged With: AbbVie, Allergan, FDA, Ideal Implant

AbbVie gains U.S. nod for $63B Allergan takeover

May 6, 2020 By Nancy Crotti

Pharmaceutical giant  AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its  purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Pharmaceutical, Wall Street Beat Tagged With: AbbVie, Allergan, AstraZeneca plc, Eli Lilly & Co., Federal Trade Commission (FTC), Johnson & Johnson

Miles White’s fearless strategy for growing Abbott

January 10, 2020 By Nancy Crotti

With strong leadership and a taste for risk-taking, outgoing CEO Miles White left no stone unturned as he grew Abbott into one of the world’s largest medical device companies. Few medical device companies have seen the growth and transformation that Abbott (NYSE:ABT) has seen under the leadership of Miles White. During his two decades as […]

Filed Under: Business/Financial News, Cardiovascular, Diabetes, Diagnostics, Featured, Implants, Neuromodulation/Neurostimulation, Pharmaceutical, Vascular, Wall Street Beat Tagged With: Abbott, AbbVie, Guidant Corp., Hospira Inc., stjudemedical

AbbVie to buy Allergan for $6.3B

June 25, 2019 By Nancy Crotti

Pharmaceutical giant AbbVie (NYSE:ABBV) said today it will acquire Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. AbbVie will pay Allergan shareholders $188.24 per share of Allergan stock, a 45% premium to yesterday’s closing price. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: AbbVie, Allergan

FDA approves J&J’s Tremfya self-injection pen for psoriasis

January 30, 2019 By Nancy Crotti

FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie’s (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Get the full story on our sister site, Drug Delivery Business.

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), News Well Tagged With: AbbVie, FDA, Janssen Pharmaceuticals, Johnson and Johnson

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS